Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.
about
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional studyEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsTherapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.Treatment continuation in patients receiving biological agents or conventional DMARD therapy.Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activityDuration of rheumatoid arthritis influences the degree of functional improvement in clinical trials.Leflunomide in active rheumatoid arthritis: a prospective study in daily practiceMedication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.Great expectations of modern RA treatmentLeflunomide and methotrexate combination therapy in daily clinical practice.Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
P2860
Q24673434-2C4CD411-2676-4A2E-AFE0-C660BCC00440Q33956623-0AB77919-7FD8-45AA-9B34-D1B35B23CB97Q34110066-ADC9A23E-A0C9-4D06-9804-BA9867F4AFCCQ35555376-190C8588-24AE-4056-A970-1B465B482479Q35556040-5A7B184B-D529-4FD2-B1FC-6364685D7C22Q35605553-318ACA68-42F0-4835-9D68-E27CA3CC1854Q35636722-BBB1EF87-07AD-4DA6-A3D2-2A3774031F6CQ35826170-13B9FFD0-EE88-4C0E-8F6C-A9FFCA0CFD10Q37207129-4C24FF40-1D0D-4F60-A4C0-7CABCFCD733DQ37358239-A8B8804E-8193-42E7-A8B0-8ED7CB03B248Q42011564-CF299C70-9AFC-4915-A9EE-C66CEB4C0C9CQ42955880-A1FEF829-540E-4A43-8EC6-8EE1F215A5E0Q55540665-AC2E17AB-7C1D-4A82-937E-6085C6B8B8E5
P2860
Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@ast
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@en
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@en-gb
type
label
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@ast
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@en
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@en-gb
prefLabel
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@ast
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@en
Efficacy and safety of lefluno ...... rthritis: RELIEF 6-month data.
@en-gb
P2093
P1476
Efficacy and safety of lefluno ...... arthritis: RELIEF 6-month data
@en
P2093
Cristiano A Zerbini
Ernst-Martin Lemmel
Maxime Dougados
Paul Emery
Piet van Riel
Rodriguez de la Serna
Sylvie Brin
P304
P407
P577
2003-12-01T00:00:00Z